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Abstract
Background: Niemann-Pick type C (NPC) disease is a lysosomal storage disease characterized by the accumulation of
cholesterol and glycosphingolipids. The majority of NPC patients die in their teen years due to progressive
neurodegeneration; however, half of NPC patients also suffer from cholestasis, prolonged jaundice, and hepatospleno-
megaly. We previously showed that a key mediator of NPC liver disease is tumor necrosis factor (TNF) a, which is involved in
both proinflammatory and apoptotic signaling cascades. In this study, we tested the hypothesis that blocking TNF action
with an anti-TNF monoclonal antibody (CNTO5048) will slow the progression of NPC liver disease.
Methodology/Principal Findings: Treatment of wild-type C57BL/6 mice with NPC1-specific antisense oligonucleotides led to
knockdown of NPC1 protein expression in the liver. This caused classical symptoms of NPC liver disease, including hepatic cholesterol
accumulation, hepatomegaly, elevated serum liver enzymes, and lipid laden macrophage accumulation. In addition, there was a
significant increase in the number of apoptotic cells and a proliferation of stellate cells. Concurrent treatment of NPC1 knockdown
mice with anti-TNF had no effect on the primary lipid storage or accumulation of lipid-laden macrophages. However, anti-TNF
treatment slightly blunted the increase in hepatic apoptosis and stellate cell activation that was seen with NPC1 knockdown.
Conclusions/Significance: Current therapeutic options for NPC disease are limited. Our results provide proof of principle
that pharmacologically blocking the TNF-a inflammatory cascade can slightly reduce certain markers of NPC disease. Small
molecule inhibitors of TNF that penetrate tissues and cross the blood-brain barrier may prove even more beneficial.
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Introduction
Niemann-Pick type C (NPC) disease is an autosomal recessive
lysosomal storage disease characterized by the accumulation of
cholesterol and glycosphingolipids. Ninety-five percent of clinical
cases are caused by mutations in the NPC1 gene [1]. Symptoms of
NPC include vertical gaze palsy, ataxia, dystonia and progressive
neurodegeneration [2]. The majority of NPC patients die in their
teen years due to their neurodegeneration; however, their liver
disease is also significant [3]. Approximately half of NPC patients
sufferfrom cholestasis, prolonged jaundiceand hepatosplenomegaly
[1,4,5]. NPC1-deficient mice show hepatic cholesterol accumula-
tion, hepatomegaly, elevated serum liver enzymes, and increased
apoptosis [6,7,8,9,10,11]. Lipid-laden macrophages accumulate
and recruit inflammatory cells [11]. Stellate cells proliferate and
deposit collagen, leading to fibrosis. The mechanism by which
NPC1 dysfunction leads to liver disease is unknown.
We previously showed that tumor necrosis factor (TNF) a is a
key mediator of NPC liver disease [12]. TNF-a is an inflammatory
cytokine that is secreted by foamy macrophages. It recruits
inflammatory cells, stimulates hepatic stellate cells, and activates
an apoptotic signaling cascade. We determined that liver-specific
knockdown of NPC1 in TNF-a deficient mice leads to attenuated
hepatocyte apoptosis, fibrosis and foamy macrophage clustering
into granulomas.
In this study, we have tested the hypothesis that blocking TNF-a
action with an anti-TNF-a monoclonal antibody (CNTO5048)
will slow the progression of NPC liver disease. Targeting TNF-a
mediated inflammation is not expected to halt the primary
lysosomal lipid accumulation, but it may reduce secondary
consequences of NPC liver disease. Our results indicate that
anti-TNF treatment has only a modest effect in blunting the
hepatic apoptosis and stellate cell activation that is characteristic of
NPC disease.
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Anti-TNF suppresses the TNF-a response induced by an
LPS challenge
To ensure that anti-TNF is efficacious in our model system, we
treated wild-type mice for 7 days with either anti-TNF or saline.
We then challenged the mice with injection of either lipopolysac-
charide (LPS) or saline. The pathological effects of LPS are, in
part, mediated by the release of TNF-a [13]. We assessed the
ability of the monoclonal antibody to neutralize TNF-a by
measuring the plasma concentration of the downstream pro-
inflammatory cytokine, IL-6, three hours after LPS injection.
Control mice treated with saline injections and no LPS
challenge had undetectable plasma levels of IL-6 (,4 pg/ml).
Two mice treated with saline injections and then subjected to an
LPS challenge had 68 and 74 ng/ml of plasma IL-6. Two mice
treated with anti-TNF injections and then subjected to an LPS
challenge had reduced levels of plasma IL-6, at 27 and 29 ng/ml.
Hepatic NPC1 knockdown in mice caused TNF-a-mediated
hepatic inflammation that was markedly less severe than that seen
with LPS treatment. We injected three mice with NPC1-specific
antisense oligonucleotides (ASOs) twice a week for 15 weeks to
induce NPC liver disease [14] and found undetectable levels of IL-
6( ,4 pg/ml). Since anti-TNF was able to blunt the massive
inflammatory response elicited by LPS, we reasoned that it would
be able to suppress the more modest inflammation that results
from hepatic NPC1 knockdown.
Anti-TNF treatment of NPC1 knockdown mice does not
alleviate hepatic lipid storage
Our experimental protocol had twenty C57BL/6 mice divided
into four treatment groups. Ten mice each were injected twice a
week with NPC1-specific ASOs or with mismatched control
ASOs. Five mice in each group were injected once a week with
saline or with the anti-TNF-a monoclonal antibody. NPC1
protein levels in the liver were knocked down to less than 10%
of control levels by NPC1 ASO treatment (Fig. 1A). Anti-TNF
treatment had no effect on NPC1 protein levels (data not shown).
NPC1 knockdown in saline-treated mice led to a small but
significant increase in body and liver weights (p,0.05) when
compared to mismatched ASO controls (Fig. 1B and 1C). NPC1
knockdown in anti-TNF-treated mice led to a small increase in
body and liver weights.
Previously, we showed that TNF-a does not play a role in the
development of the primary storage phenotype of NPC [12]. Our
new results are consistent with the previous report. Here we found
that NPC1 knockdown led to a five-fold increase in hepatic
unesterified cholesterol content (p,0.01) (Fig. 1D). The same
increase in hepatic cholesterol content was seen when NPC1 was
knocked down in anti-TNF-treated mice. Thus, as expected, the
anti-TNF treatment had no effect on the cholesterol storage that
results from NPC1 dysfunction.
Serum alanine aminotransferase (ALT) activity was measured in
the four treatment groups to determine whether anti-TNF
treatment of NPC1 knockdown mice resulted in less liver injury.
Mice injected with mismatched ASOs and treated with saline or
anti-TNF had similar serum ALT activities of 23.664.5 and
25.265.4 U/L, respectively. NPC1 knockdown led to a significant
increase in serum ALT to 98612.9 U/L. The serum ALT activity
of NPC1 knockdown mice was not significantly reduced by anti-
TNF treatment (78.3620.7 U/L). These data indicate that anti-
TNF has no effect on the hepatic injury that leads to enzyme
release.
Sections of mismatched, control ASO-treated livers showed few
foamy, vacuolated macrophages (seen in Fig. 2 and quantified in
Fig. 3A). Saline and anti-TNF-treated liver sections were
indistinguishable. NPC1 knockdown led to a 10-fold increase in
the number of foamy and vacuolated macrophages. Knockdown
Figure 1. Effect of NPC1 knockdown and anti-TNF treatment on
NPC1 protein levels, whole body weight, liver weight, and
hepatic cholesterol content. A: Expression of NPC1 in livers of mice
injected for 9 weeks with mismatched (MM) and NPC1-specific ASOs
and subjected to treatment (TX) with saline or anti-TNF. b-Actin was
used as a loading control. Whole body weight (B), relative liver weight
(C) and hepatic unesterified cholesterol content (D) in mice injected
with mismatched (MM) and NPC1-specific ASOs and subjected to
treatment (TX) with saline or anti-TNF. Each bar represents the mean 6
SD of 5 animals in each treatment group. The lettering (a, b) shows
statistically dissimilar groups. Samples with two letters represent values
that are intermediate to the statistical groups and are thus not
considered significantly different from either group.
doi:10.1371/journal.pone.0012941.g001
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identical number of foamy macrophages. In both cases, the
number of hepatocytes per field declined commensurate with the
appearance of foamy macrophages (Fig. 3B).
Thus far there was only one indication that anti-TNF has a
therapeutic effect on the NPC knockdown mice. That is that the
liver weight did not increase significantly when NPC was knocked
down in anti-TNF-treated mice. Next we examined the down-
stream consequences of hepatic lipid accumulation.
Anti-TNF has a slight effect on hepatocyte apoptosis and
stellate cell activation
Knockdown of NPC1 was shown previously to result in a 10-
fold increase in the number of apoptotic hepatocytes, which was
offset by proliferation of hepatic stellate cells [11]. In this study, we
found 0.6 apoptotic cells per field in TUNEL-stained liver sections
from mice injected with mismatched ASOs and treated with either
saline or anti-TNF (Fig. 4). The number of apoptotic cells
increased 5-fold by NPC1 knockdown (p,0.05). Anti-TNF
treatment provided some protective effect in that NPC1
knockdown in anti-TNF-treated mice led to an intermediate 3-
fold increase in the number of apoptotic cells.
NPC1 knockdown also results in increased proliferation of
hepatic stellate cells, which can be visualized by a-smooth muscle
actin immunohistochemistry (Fig. 5A). Quantification of the a-
smooth muscle actin-positive cells revealed a 3-fold increase in
stellate cells when NPC1 was knocked down in saline-treated mice
(p,0.05). Again, anti-TNF treatment of NPC1 knockdown mice
led to a smaller increase in proliferating stellate cells (Fig. 5B).
Thus, the second and third indications that anti-TNF had a
therapeutic effect were that the numbers of apoptotic cells and
proliferating stellate cells did not increase significantly when NPC1
was knocked down in anti-TNF treated mice.
Discussion
The goal of the current study was to evaluate an anti-TNF-a
monoclonal antibody as a potential therapeutic modality for NPC
disease. Our previous results had shown that TNF-a mediates some
of the secondary consequences of NPC disease in the liver. NPC1
knockdown mice showed hepatomegaly, liver cholesterol accumula-
tion, elevated serum liver enzymes, increased hepatocyte apoptosis
and activation of stellate cells [11]. NPC1 knockdown in mice lacking
TNF-a showed less clustering of macrophages into lipogranulomas,
fewer apoptotic cells, reduced fibrosis and fewer activated stellate cells
[12]. Thus, the lack of TNF appeared to slow the progression of NPC
liver disease. Our hypothesis was that anti-TNF treatment of NPC1
knockdown mice would lead to a similar moderated phenotype.
Our results show that, as expected, anti-TNF had no effect on
the primary NPC phenotype. NPC1 knockdown mice treated with
vehicle or anti-TNF showed the same hepatic cholesterol storage,
number of foamy cells throughout the hepatic parenchyma and
release of liver enzymes into the blood. Anti-TNF treatment of
NPC1 knockdown mice led to fewer apoptotic hepatocytes and
Figure 2. Hepatic formation and clustering of foamy macrophages in NPC1 knockdown mice. Masson’s trichrome stained liver sections
from mice injected for 9 weeks with mismatched (MM) and NPC1-specific ASOs and subjected to treatment with saline or anti-TNF. Images were
photographed at 200X magnification.
doi:10.1371/journal.pone.0012941.g002
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attenuation did not reach statistical significance. Instead, anti-TNF
treatment led to a phenotype that was intermediate between
control and NPC1 knockdown.
NPC is a lysosomal storage disease with a primary impairment
in intracellular cholesterol trafficking [15]. The defective export of
cholesterol from lysosomes leads to a cellular accumulation of
lipid-laden storage bodies and a deficiency of cholesterol transfer
to the plasma membrane. NPC patients exhibit progressive
neurodegeneration and hepatosplenomegaly, and have limited
therapeutic options [16]. Several lines of evidence indicate that
inflammation plays a role in the secondary consequences of the
disease. The NPC brain and liver show increased expression of
TNF-a and other members of the pro-inflammatory TNF-a
pathway [6,17,18,19].
Here we tested whether anti-TNF treatment would be efficacious
for NPC patients. The monoclonal antibody that we used in our
study binds and neutralizes murine TNF-a; it was a surrogate for
infliximab, a monoclonal antibody that binds the membrane-bound
and soluble forms of human TNF-a and prevents their binding to
cellular receptors [20]. Infliximab (RemicadeH) has been approved
by use in patients with immune-mediate inflammatory diseases,
such as Crohn’s disease, rheumatoid arthritis, and psoriasis. In
NPC1 knockdown mice, anti-TNF reduced some of the down-
stream effects of inflammationinthe liver, but was not as effective as
genetic knockout of TNF-a expression [12]. The weak effect of anti-
TNF was seen when treatment was administered coincident with
NC1 knockdown and prior to the onset of NPC liver disease. We
expect it would have less benefit when given to NPC patients, who
are typically diagnosed after tissue damage has taken place. These
results may presage the need for small molecular inhibitors of the




The 20-mer 29-0-methoxyethyl modified ASOs were synthe-
sized and purified as described previously [21,22]. The sequence
of the ASO targeted to the NPC1 mRNA is: 59CCCGATT-
GAGCTCATCTTCG39. As a control, we used an ASO with a
mismatched sequence 59CCTTCCCTGAAGGTTCCTCC39.
ASOs were dissolved in 0.9% saline and stored at 220uC.
Animal Care and Treatment
Ethics Statement: All of the following procedures were approved
by the Institutional Animal Care and Use Committee at Tufts
University (Animal Welfare Assurance Number A-3775-01,
protocol #71-06) and were in compliance with the NIH Guide
for the Care and Use of Laboratory Animals.
Female C57BL/6 mice (4 wks of age) were purchased from The
Jackson Laboratory (Bar Harbor, ME). They were housed 5
animals per cage and fed rodent chow. Mice were challenged with
LPS by intraperitoneal injection of 200 ml of a 1-mg/ml solution
(Sigma L5293). Mice were injected intraperitoneally with either
NPC1 ASO or a mismatched control ASO at a dose of 100 mg/
kg/wk for 9 weeks. They were also injected intraperitoneally with
either saline or an anti-TNF monoclonal antibody (CNTO5048) at
a dose of 12 mg/kg/wk for 9 weeks. At the end of the treatment
period, animals were fasted overnight, then euthanized and blood
samples taken by cardiac puncture. Mice were perfused with cold
PBS via cardiac puncture, after which tissues were dissected and
fixed in 10% formalin or snap-frozen in liquid nitrogen.
Figure 4. Effect of NPC1 knockdown and anti-TNF treatment on
hepatic apoptosis. Liver sections from mice injected for 9 weeks with
mismatched (MM) and NPC1-specific ASOs and subjected to treatment
(TX) with saline or anti-TNF were subjected to fluorometric TUNEL
staining. Apoptotic nuclei were quantified. Each bar represents the
mean 6 SD number of cells per field from 5 animals in each treatment
group. The lettering (a, b) shows statistically dissimilar groups. Samples
with two letters represent values that are intermediate to the statistical
groups and are thus not considered significantly different from either
group.
doi:10.1371/journal.pone.0012941.g004 Figure 3. Effect of NPC1 knockdown and anti-TNF treatment on
the number of foamy macrophages and hepatocytes. Quantifi-
cation of foamy macrophages (A) and hepatocytes (B) in H&E stained
liver sections from mice injected for 9 weeks with mismatched (MM)
and NPC1-specific ASOs and subjected to treatment (TX) with saline or
anti-TNF. Each bar represents the mean 6 SD number of cells per field
from 3 animals in each treatment group. The lettering (a, b) shows
statistically dissimilar groups.
doi:10.1371/journal.pone.0012941.g003
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Liver tissue was blotted for NPC1 as previously described [11]
using an NPC1 antibody from Abcam, Cambridge, MA. Anti-b-
actin monoclonal antibody (Sigma) was used at 1:15,000 dilution.
Measurement of Cholesterol Content
Aliquots of 400 mg liver homogenate were subjected to Folch
extraction [23]. Stigmasterol (45 mg) was added to each sample as
an internal standard. The Folch organic phase was injected into a
Hewlett-Packard 5890 gas chromatograph with a DB-17 capillary
column (15 m60.53 mm, Alltech) held at 255uC.
Serum Chemistries
Blood was allowed to clot for 30 min, then subjected to
centrifugation at 10006 g for 30 minutes. Serum was sent to
IDEXX Laboratories (Grafton, MA) for analysis of liver enzymes.
Figure 5. Stellate cell activation after NPC1 knockdown and anti-TNF treatment. Liver sections from mice injected for 9 weeks with
mismatched (MM) and NPC1-specific ASOs and subjected to treatment with saline or anti-TNF were subjected to a-smooth muscle actin
immunohistochemistry (A). Immunohistochemical reaction product was quantified (B). Each bar represents the mean6 SD relative area of
brownreactionproduct per field from 5animals in each treatment group.Thelettering (a, b) shows statistically dissimilargroups.Samples with
two letters represent values that are intermediate to the statistical groups and are thus not considered significantly different from either
group.
doi:10.1371/journal.pone.0012941.g005
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Liver tissue was fixed in 10% formalin and paraffin embedded.
Four-micron sections were cut and stained with Masson
Trichrome, hematoxylin-eosin or anti-a smooth muscle actin by
the Tufts Animal Histology Core or the Tufts Medical Center
Histology Department. Slides were viewed using a Zeiss Axioplan
microscope with a 20X objective. The number of hepatocytes and
foamy macrophages were quantified per field. a-Smooth muscle
actin immunohistochemistry was quantified using ImageJ. For all
analyses, 10 random fields were examined per liver; 3–5 animals
were evaluated per treatment group.
Detection of Apoptotic Cells
Apoptotic cells in formalin-fixed, paraffin-embedded liver tissue
sections were detected using the DeadEnd Fluorometric TUNEL
System (Promega, Madison, WI) according to the manufacturer’s
protocol. The number of apoptotic cells was quantified per field.
Ten random fields were examined per liver; 5 animals were
evaluated per treatment group.
Statistical Analysis
All values are expressed as means 6 SD. Statistical analysis was
performed by one way ANOVA followed by Tukey’s honestly
significant differences test using the Vassar Stats website.
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